AVANOS MEDICAL, INC. — fact timeline

AVANOS MEDICAL, INC. reported financial results for the three months ended March 31, 2026.

“On May 5, 2026, Avanos Medical, Inc. issued a press release announcing its results of operations for the three months ended March 31, 2026.”

AVANOS MEDICAL, INC. entered into Agreement and Plan of Merger with A-AV Holdco I, Inc. and A-AV MergerSub, Inc. valued at $25.00 per Share in cash (effective 2026-04-13).

“On April 13, 2026, Avanos Medical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, A-AV Holdco I, Inc., a Delaware corporation (“Parent”), and A-AV MergerSub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Subsidiary”).”

Michael C. Greiner departed as other_named_officer at AVANOS MEDICAL, INC..

“On April 28, 2025, Avanos Medical, Inc. (the “Company”) and Michael C. Greiner entered into a Separation and Consulting Agreement (the “Separation and Consulting Agreement”).”

Warren J. Machan departed as Interim Chief Financial Officer at AVANOS MEDICAL, INC..

“Mr. Machan no longer serves as the Company’s Interim Chief Financial Officer effective April 14, 2025”

Jason M. Pickett was appointed as Interim Chief Financial Officer and Treasurer at AVANOS MEDICAL, INC..

“The Company has appointed Jason M. Pickett as Interim Chief Financial Officer and Treasurer, effective April 14, 2025.”

Michael C. Greiner departed as Senior Vice President, Chief Financial Officer and Chief Transformation Officer at AVANOS MEDICAL, INC..

“On April 18, 2025, Michael C. Greiner announced that he will leave the Company to pursue other opportunities because the Company did not offer him a position comparable to the one he held prior to his role as the Company’s Interim Chief Executive Officer.”

Jason M. Pickett was appointed as Interim Chief Financial Officer and Treasurer at AVANOS MEDICAL, INC..

“The Company has appointed Jason M. Pickett as Interim Chief Financial Officer and Treasurer, effective April 14, 2025.”

Warren J. Machan departed as Interim Chief Financial Officer at AVANOS MEDICAL, INC..

“Mr. Machan no longer serves as the Company’s Interim Chief Financial Officer effective April 14, 2025”

Michael C. Greiner departed as Senior Vice President and Chief Financial Officer at AVANOS MEDICAL, INC..

“On April 18, 2025, Michael C. Greiner announced that he will leave Avanos Medical, Inc. (the “Company”) to pursue other opportunities because the Company did not offer him a position comparable to the one he held prior to his role as the Company’s Interim Chief Executive Officer.”

David Pacitti was appointed as Chief Executive Officer at AVANOS MEDICAL, INC..

“On March 17, 2025, Avanos Medical, Inc. (the “Company”) announced the appointment of David Pacitti as the Company’s Chief Executive Officer, effective April 14, 2025.”

David Pacitti was appointed as Chief Executive Officer at AVANOS MEDICAL, INC..

“On March 17, 2025, Avanos Medical, Inc. (the “Company”) announced the appointment of David Pacitti as the Company’s Chief Executive Officer, effective April 14, 2025.”

Michael C. Greiner was appointed as Interim Chief Executive Officer at AVANOS MEDICAL, INC..

“the Company appointed Michael C. Greiner to serve as Interim Chief Executive Officer of the Company.”

Joseph F. Woody retired as Chief Executive Officer at AVANOS MEDICAL, INC..

“On October 28, 2024, the Company announced the retirement of Joseph F. Woody as Chief Executive Officer and a member of the Board of Directors of the Company, effective immediately.”

Indrani Franchini was appointed as Director at AVANOS MEDICAL, INC..

“On June 28, 2024, the Board of Directors (the “Board”) of Avanos Medical, Inc. (the “Company”) appointed Indrani Franchini to the Board, effective July 1, 2024.”

AVANOS MEDICAL, INC. reported financial results for three months ended March 31, 2024.

“On May 2, 2024, Avanos Medical, Inc. (the "Company") issued a press release announcing its results of operations for the three months ended March 31, 2024.”

AVANOS MEDICAL, INC. shareholders approved To approve, on an advisory basis, the compensation of the Company’s named executive officers at the 2024-04-25 meeting.

“The votes cast on Proposal No. 3 were as follows: For Against Abstain Broker non-votes Approval of NEO compensation 38,515,084 2,104,432 57,555 2,312,795”

AVANOS MEDICAL, INC. shareholders approved To ratify the appointment of Deloitte & Touche LLP as the Company’s independent auditors for 2024 at the 2024-04-25 meeting.

“The votes cast on Proposal No. 2 were as follows: For Against Abstain Appointment of Deloitte & Touche LLP 42,503,768 435,813 50,285”

AVANOS MEDICAL, INC. shareholders approved To elect Gary D. Blackford, Dr. Lisa Egbuonu-Davis, Patrick J. O’Leary, Dr. Julie Shimer and Joseph F. Woody to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders at the 2024-04-25 meeting.

“The votes cast on Proposal No. 1 were as follows: Director For Withhold Broker non-votes Gary D. Blackford 39,916,596 760,475 2,312,795 Dr. Lisa Egbuonu-Davis 39,845,016 832,055 2,312,795 Patrick J. O’Leary 40,149,326 527,745 2,312,795 Dr. Julie Shimer 39,726,238 950,833 2,312,795 Joseph F. Woody 40,385,119 291,952 2,312,795”

AVANOS MEDICAL, INC. reported fourth quarter and full-year 2023 results: revenue Fourth quarter net sales from continuing operations totaled $173.3 million, a 4.6% decrease from the prior year. For the, EPS Fourth quarter diluted earnings per share from continuing operations were $0.24 compared to diluted earnings per share o.

“Fourth quarter net sales from continuing operations totaled $173.3 million, a 4.6% decrease from the prior year. For the full-year, net sales from continuing operations decreased 1.6% to $673.3 million. • Fourth quarter diluted earnings per share from continuing operations were $0.24 compared to diluted earnings per share of $0.21 per share a year ago, and fourth quarter adjusted diluted earnings per share from continuing operations were $0.36 compared to $0.45 in the prior year. 2023 full-year diluted loss per share from continuing operations were $0.21 compared to diluted earnings per share of $0.46 in the prior year, and adjusted diluted earnings per share from continuing operations were $1.03 compared to $1.00 in 2022.”

AVANOS MEDICAL, INC. reported preliminary financial results for the quarter and full-year ended December 31, 2023.

“On January 4, 2024, Avanos Medical, Inc. (the “Company”) issued a press release that announced selected, unaudited preliminary financial results for the quarter and full-year ended December 31, 2023.”